Identifying Risk Factors That Distinguish Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection From Common Upper Respiratory Infections in Children.

Background Demographic and clinical risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children presenting with respiratory viral symptoms are not well defined. An understanding of risk factors for SARS-CoV-2 infection can help prioritize testing. Methodology We evaluated potential demographic and clinical factors in children who had respiratory viral symptoms and were tested by polymerase chain reaction (PCR) for SARS-CoV-2 and other respiratory viral infections.

Synthea™ Novel coronavirus (COVID-19) model and synthetic data set.

March through May 2020, a model of novel coronavirus (COVID-19) disease progression and treatment was constructed for the open-source Synthea patient simulation. The model was constructed using three peer-reviewed publications published in the early stages of the global pandemic, when less was known, along with emerging resources, data, publications, and clinical knowledge. The simulation outputs synthetic Electronic Health Records (EHR), including the daily consumption of Personal Protective Equipment (PPE) and other medical devices and supplies.

Synthea: An approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record.

Objective: Our objective is to create a source of synthetic electronic health records that is readily available; suited to industrial, innovation, research, and educational uses; and free of legal, privacy, security, and intellectual property restrictions.

Materials And Methods: We developed Synthea, an open-source software package that simulates the lifespans of synthetic patients, modeling the 10 most frequent reasons for primary care encounters and the 10 chronic conditions with the highest morbidity in the United States.

Results: Synthea adheres to a previously developed conceptual framework, scales via open-source deployment on the Internet, and may be extended with additional disease and treatment modules developed by its user community.